However, of note, when the nucleus translocation of β-catenin signaling was efficiently inhibited by Tegatrabetan (BC2059) treatment (100 nM; cat#,S0733, Selleck) in gastric cancer cells, KMT2A overexpression did not significantly upregulate the levels of these stemness-related molecules (Figure 3g) and rescue the proliferation (Figure 3h) as well as inhibit the apoptosis of gastric cancer cells (Figure 3i–l), compared to the KMT2A overexpression alone. Here, KMT2A is linked to gastric cancer.